CLBS119 / Lisata Therap - LARVOL DELTA

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Caladrius Biosciences, Inc.; N=12 ➔ 0; Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

[VIRTUAL] Autologous Cd34+ Cells (clbs119) for Repair of Covid-19 Induced Microvascular Lung Damage: Rationale and Study Design (AHA 2020) - "CD34+ cells will be mobilized with plerixafor and selected from the mononuclear fraction following apheresis. Subjects will be followed for 6 months following administration. Interim findings will be presented."

Fibrosis • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • CD34

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Caladrius Biosciences, Inc.; Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage (GlobeNewswire) - "Caladrius Biosciences, Inc....announced that it has opened its proof-of-concept study of CLBS119 as a treatment for COVID-19-induced lung damage and begun screening prospective patients for inclusion at NYU Langone Health. This planned 12-patient open-label clinical trial is designed to evaluate the safety and efficacy of a single administration of CLBS119....for the treatment and repair of COVID-19-induced lung damage in adults. The study will target patients who are experiencing hypoxia due to prior infection with SARS-CoV-2 and who require supplemental oxygen."

Enrollment open • Infectious Disease • Novel Coronavirus Disease

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Caladrius Biosciences, Inc.

New P1 trial • Infectious Disease • Novel Coronavirus Disease

Caladrius Biosciences to present on CLBS119 for Covid-19 induced lung damage at the BioNJ Covid-19 rapid fire research showcase (GlobeNewswire) - "Caladrius Biosciences, Inc....today announced that the company has been selected to present at the BioNJ COVID-19 Rapid Fire Research Showcase on Friday, June 5, 2020. David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius Biosciences, will present an overview of CLBS119, Caladrius’ CD34+ cell therapy product candidate targeting repair of COVID-19 induced lung damage."

Live event • Infectious Disease • Novel Coronavirus Disease